Notably, our findings lend support to the notion that CCN3 levels in CAD patients increase independently of obesity and insulin resistance parameters, thus potentially serving as a robust biomarker for the prognosis of CAD patients. The gene discussed is CCN3; the disease is obesity due to melanocortin 4 receptor deficiency.